Intravitreal brolucizumab shows promise in chronic central serous chorioretinopathy Intravitreal brolucizumab appears to be efficacious for achieving fluid resolution and reducing macular thickness in chronic central serous chorioretinopathy with persistent fluid.

#MedNews - Intravitreal #brolucizumab appears to be efficacious for achieving fluid resolution and reducing macular thickness in chronic central serous #chorioretinopathy with persistent fluid.

Full story 👉 buff.ly/32omyC5

#EyeSky